OMEROS CORPORATION
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $238.1M
- Website
- http://www.omeros.com/
Clinical Trials
57
Trial Phases
3 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (49 trials with phase data)• Click on a phase to view related trials
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06298955
- Locations
- 🇬🇧
Omeros Investigational Site, Leeds, United Kingdom
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
- Conditions
- C3 GlomerulopathyIdiopathic Immune Complex-Mediated Glomerulonephritis
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT06209736
- Locations
- 🇬🇧
Omeros Investigational Site, Newcastle Upon Tyne, United Kingdom
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 12
- Registration Number
- NCT05972967
- Locations
- 🇬🇧
Omeros Investigational Site, Leeds, United Kingdom
Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT05889299
- Locations
- 🇺🇦
Omeros Investigational Site, Kyiv, Ukraine
Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
- Conditions
- Thrombotic MicroangiopathiesHematopoietic Stem Cell Transplantation
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Omeros Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT05855083
- Locations
- 🇪🇸
Omeros Investigational Site, Pamplona, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Omeros Restructures $80.5 Million in Debt, Significantly Reducing Near-Term Financial Obligations
Omeros Corporation has entered into agreements to exchange $70.5 million of its 2026 Convertible Notes for new 2029 Convertible Notes with a 9.50% interest rate, extending debt maturity by three years.
IgA Nephropathy Pipeline Shows Robust Growth with 30+ Therapies in Development
DelveInsight's 2025 pipeline analysis reveals over 30 companies developing 30+ therapies for IgA nephropathy treatment, representing a robust therapeutic landscape.
Omeros Forms Elite Clinical Steering Committee to Advance Novel AML Therapeutic Program
Omeros Corporation has established an Oncology Clinical Steering Committee comprising eight distinguished leukemia experts from leading cancer centers to guide its OncotoX-AML program development.
Omeros Advances Zaltenibart Phase 3 Trials for PNH with Potential Superiority Over Current Treatments
Omeros Corporation has initiated site activation for its Phase 3 clinical trials of zaltenibart (OMS906) in paroxysmal nocturnal hemoglobinuria (PNH), with data for regulatory submission expected in Q4 2026.
Narsoplimab Shows Promising Real-World Outcomes in TA-TMA Patients at 2025 Tandem Meetings
Omeros Corporation will present real-world data from 128 transplant patients treated with narsoplimab for TA-TMA under an expanded access program at the 2025 Tandem Meetings in Honolulu.